The primary outcome measure was change from baseline in the number and peak severity of migraine attacks during each double-blind phase. The secondary outcome was the proportion of patients who responded to each treatment with at least a 50% reduction in migraine attacks relative to baseline. Safety was assessed by reports of adverse events.